scispace - formally typeset
L

L. Nelson Hopkins

Researcher at University at Buffalo

Publications -  406
Citations -  19084

L. Nelson Hopkins is an academic researcher from University at Buffalo. The author has contributed to research in topics: Stroke & Angioplasty. The author has an hindex of 68, co-authored 399 publications receiving 17634 citations. Previous affiliations of L. Nelson Hopkins include University at Albany, SUNY & Women & Children's Hospital of Buffalo.

Papers
More filters
Journal ArticleDOI

The CAPTURE registry: Predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting

TL;DR: Predictors of outcomes in carotid stenting in the earliest and largest prospective multicenter neurologist‐adjudicated experience in the United States post device approval are examined.
Journal ArticleDOI

The CAPTURE registry: results of carotid stenting with embolic protection in the post approval setting.

TL;DR: The results of the CAPTURE study suggest that the post‐approval transfer of this new therapy to the community practice setting via carotid stent training programs is effective in preparing physicians with varying experience levels and specialty training backgrounds.
Journal ArticleDOI

Aggressive Mechanical Clot Disruption and Low-dose Intra-arterial Third-generation Thrombolytic Agent for Ischemic Stroke: A Prospective Study

TL;DR: A high rate of recanalization and clinical improvement can be observed in patients with ischemic stroke using low-dose thrombolytic agents with adjunctive mechanical disruption of clot, and this strategy may reduce the risk of intracerebral hemorrhage observed with throm bolytics.
Journal ArticleDOI

Safety and effectiveness of the INVATEC MO.MA proximal cerebral protection device during carotid artery stenting: results from the ARMOUR pivotal trial.

TL;DR: The ARMOUR trial demonstrated that the MO.MA® Proximal Cerebral Protection Device is safe and effective for high surgical risk patients undergoing CAS, and the absence of stroke in symptomatic patients is the lowest rate reported in any independently adjudicated prospective multicenter registry trial to date.